Drugs R D (2018) 18:163 https://doi.org/10.1007/s40268-018-0234-z CORRECTION Correction to: Feasibility, Safety, and Efﬁcacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 1 2 1 1 • • • • Sebastiano Buti Maddalena Donini Melissa Bersanelli Alessia Gattara 1 2 Francesco Leonardi Rodolfo Passalacqua Published online: 28 May 2018 The Author(s) 2018 Open Access This article is distributed under the terms of the Correction to: Creative Commons Attribution-NonCommercial 4.0 International Drugs R D https://doi.org/10.1007/s40268-017-0209-5 License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any In the Original Publication of the article, In Introduction medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and part, 7th line, the value ‘‘5–100 nM’’ has been published indicate if changes were made. incorrectly. The correct value should read as ‘‘Plasma concentration of 50–100 ng/ml’’. In the Original Publica- tion of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown below: Table 2 Delivered treatment, dose reductions and interruptions Sunitinib 4/2 schedule Sunitinib modiﬁed schedule Median time from start to switch, months (range) 2.9 (1.4–16.5) – Median duration of treatment after switch, months (range) – 9.2 (0.5–32.4) Mean actual daily dose intensity, mg (range) 46.1 (20.8–50.0) 44.3 (17.9–71.8) Mean relative dose intensity, % (range) 92.3 (42–100) 88.7 (36–144) Total cycles, number 88 164 Median cycles, number (range) 2 (1–11) 5 (1–20) Patients with a dose reduction, number (%) 3 (12) 3 (12) Patients with a dose interruption, number (%) 7 (28) 12 (48) Number of dose interruptions corrected for number of cycles (%) 0.10 (10) 0.11 (11) Patients still on treatment, number (%) – 2 (16) The original article can be found online at https://doi.org/10.1007/ s40268-017-0209-5. & Melissa Bersanelli email@example.com Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy
Drugs in R&D – Springer Journals
Published: May 28, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera